MILES TO READ B4 I SLEEP: STENTRODE

Saturday, 21 March 2026

STENTRODE

Here are 3 simple key points from the article:

🧠 Brain implant control
A new implant lets people with motor neuron disease control phones or computers using only their thoughts.
🔬 Less invasive technology
The device is inserted through blood vessels (like a stent), avoiding open brain surgery.
🌍 Big future potential
This could help paralyzed patients communicate and interact with the world more easily in the future.

The Stentrode is a minimally invasive brain-computer interface (BCI) developed by the company Synchron that allows individuals with paralysis to control digital devices using only their thoughts. Unlike other BCIs that require open-brain surgery (craniotomy) to implant electrodes directly into brain tissue, the Stentrode is delivered through the venous system via the jugular vein. [1, 2, 3, 4]

Key Features and Technology

Endovascular Design: It is a 40mm-long self-expanding nitinol scaffold (stent) embedded with 16 platinum sensors.
Placement: Using standard neurointerventional techniques, it is positioned in the superior sagittal sinus, a major blood vessel sitting directly adjacent to the brain's motor cortex.
Integration: Over time, the device undergoes endothelialization, where it becomes incorporated into the blood vessel wall, protecting it from immune rejection while maintaining blood flow.
Signal Transmission: The sensors detect neural signals (local field potentials) which are sent via a lead to an Implantable Receiver-Transmitter (IRT) in the chest. This unit then wirelessly transmits the data to external devices. [5, 6, 7, 8, 9, 10]

Clinical Applications and Progress

The primary goal is to restore independence for patients with conditions like ALS, stroke, or spinal cord injury. [9, 11]

Current Capabilities: Patients in clinical trials (such as the SWITCH and COMMAND studies) have successfully used the device to text, email, shop online, and manage finances.
Performance: In early trials, participants achieved over 90% accuracy in discriminating attempted movement from rest within three months.
Safety: A year-long study of six participants in the COMMAND trial (reported in late 2024) met its primary safety endpoint with no device-related serious adverse events.
Future Potential: Synchron is exploring the use of the Stentrode for neuromodulation, which could potentially treat conditions like Parkinson’s disease, epilepsy, and depression by sending signals back to the brain. [1, 3, 6, 9, 12, 13, 14, 15, 16]